Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.75 |
| ▸ | VDR | P11473 | 13/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CDC25A | P30304 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656328 | 1.00 | ADORA3 (0.75) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL8004306 | 1.00 | ADORA3 (0.75) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL8004302 | 1.00 | ADORA3 (0.75) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL10597997 | 0.92 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL11681017 | 0.92 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL27542722 | 0.92 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL11681021 | 0.92 | ADORA3 (0.76) | ADORA3SLC6A2AGTR1VDRMEN1 | |
| SCHEMBL3181793 | 0.91 | VDR (0.76) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL6401347 | 0.91 | VDR (0.76) | ADORA3SLC6A2AGTR1VDRMAPT | |
| SCHEMBL6407006 | 0.91 | VDR (0.76) | ADORA3SLC6A2AGTR1VDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496914-B1 | (20S)-1alpha-HYDROXY-2alpha-METHYL AND 2beta-METHYL-19-NOR-VITAMIN D3 AND THEIR USES | WISCONSIN ALUMNI RES FOUND (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7205286-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7094916-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060148769-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | DELUCA HECTOR F | 2006-07-06 | — | — | US | disclosed |
| US-7064115-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050159397-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-07-21 | — | — | US | disclosed |
| US-6846811-B2 | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1496914-A1 | (20S)-1a-HYDROXY-2a-METHYL AND 2&bgr;-METHYL-19-NOR-VITAM IN D sb 3 /sb AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6844330-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-NOR-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-6844457-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-6844331-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-6844332-B2 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040152676-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-05 | — | — | US | disclosed |
| US-20040152678-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-05 | — | — | US | disclosed |
| US-20040152677-A1 | (20S)-1alpha-hydroxy-2alpha-methl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-05 | — | — | US | disclosed |
| US-20040152675-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-08-05 | — | — | US | disclosed |
| US-20040152679-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-05 | — | — | US | disclosed |
| US-20040152680-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-05 | — | — | US | disclosed |
| US-20030203882-A1 | (20S) 1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-10-30 | — | — | US | disclosed |
| WO-2003088977-A1 | (20S)-1α-HYDROXY-2α-METHYL AND 2β-METHYL-19-NOR-VITAMIN D3 AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152679-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | CYP24A1, VDR, CYP27B1 | ADORA3 2206/4885SLC6A2 3988/4885AGTR1 3711/4885 |
| US-20050159397-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | VDR, CYP24A1, CYP27B1 | ADORA3 2474/4885SLC6A2 3765/4885AGTR1 3261/4885 |
| US-20030203882-A1 | (20S) 1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | VDR, CYP24A1, CYP27B1 | ADORA3 2185/4885SLC6A2 3977/4885AGTR1 3704/4885 |
| US-20040152680-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | CYP24A1, VDR, CYP27B1 | ADORA3 2206/4885SLC6A2 3988/4885AGTR1 3711/4885 |
| US-20040152675-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | CYP24A1, VDR, CYP27B1 | ADORA3 2206/4885SLC6A2 3988/4885AGTR1 3711/4885 |
| US-20040152677-A1 | (20S)-1alpha-hydroxy-2alpha-methl and 2beta-methyl-19-nor-vitamin D3 and their uses | CYP24A1, VDR, CYP27B1 | ADORA3 2047/4885SLC6A2 4132/4885AGTR1 3952/4885 |
| US-20040152678-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | CYP24A1, VDR, CYP27B1 | ADORA3 2206/4885SLC6A2 3988/4885AGTR1 3711/4885 |
| US-20040152676-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | CYP24A1, VDR, CYP27B1 | ADORA3 2206/4885SLC6A2 3988/4885AGTR1 3711/4885 |
| US-20060148769-A1 | (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses | VDR, CYP24A1, CYP27B1 | ADORA3 2474/4885SLC6A2 3765/4885AGTR1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.